KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Working Capital Changes: 2009-2025

Historic Other Working Capital Changes for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to $40.9 million.

  • Vertex Pharmaceuticals' Other Working Capital Changes rose 294.76% to $40.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $310.0 million, marking a year-over-year decrease of 36.34%. This contributed to the annual value of $200.3 million for FY2024, which is 63.29% down from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Other Working Capital Changes stood at $40.9 million, which was down 46.47% from $76.4 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Other Working Capital Changes registered a high of $451.3 million during Q4 2023, and its lowest value of -$99.2 million during Q1 2024.
  • In the last 3 years, Vertex Pharmaceuticals' Other Working Capital Changes had a median value of $40.9 million in 2025 and averaged $81.0 million.
  • Within the past 5 years, the most significant YoY rise in Vertex Pharmaceuticals' Other Working Capital Changes was 1,889.31% (2022), while the steepest drop was 608.27% (2022).
  • Quarterly analysis of 5 years shows Vertex Pharmaceuticals' Other Working Capital Changes stood at -$15.9 million in 2021, then soared by 1,889.31% to $284.5 million in 2022, then skyrocketed by 58.63% to $451.3 million in 2023, then plummeted by 63.53% to $164.6 million in 2024, then soared by 294.76% to $40.9 million in 2025.
  • Its Other Working Capital Changes stands at $40.9 million for Q3 2025, versus $76.4 million for Q2 2025 and $28.1 million for Q1 2025.